The Cancer Prevention and Control Center has set up a special treatment center, established special outpatient clinics and wards, and arranged famous specialists in various disciplines and experienced medical staff to carry out consultations and treatments, and the good environment and high quality services have been welcomed by people from all walks of life overseas. Over the past ten years, the hospital has treated patients with various types of tumors from Hong Kong, Macao and Taiwan compatriots, overseas compatriots and twenty-five countries and regions, ****70,000 times. The hospital always adheres to the patient-centered, the first of its kind in the country to implement computer network management, in the wards to achieve paperless prescriptions, the introduction of telephone appointments for doctors to see the doctor, the magnetic card registration and trial outpatient computer diagnosis of the system, teleconsultation services, and other new initiatives, greatly facilitating the patient, so that the waiting time for treatment is shortened by more than half. With the needs of social development, the center has built a building of 88,000 square meters building height of 25 floors, can be arranged for 1,000 beds of medical research building. The building adopts computer network intelligent management and fully enclosed central air-conditioning, rail logistics automated medical transportation system, all the equipment is synchronized with the international level, was completed and put into use on November 23, 2002, and has become the largest oncology medical teaching and research base in Asia. 2007
The center has 923 employees, including 694 health technicians, 26 with high titles, 92 with deputy high titles, and 249 with intermediate titles; 514 beds are prepared and 900 beds are actually opened. The annual outpatient and emergency treatment volume is 240,000, and the annual number of new tumor cases received is about 10,000, accounting for 18% of the new tumor cases in Guangdong Province, and 8,000 hospitalizations, all of which are ranked the first among more than 100 tumor specialty hospitals in China. The hospital provides a large number of medical and healthcare services to Hong Kong and Macao compatriots and overseas Chinese patients in South China. The hospital has a strong advantage in the overall level of tumor diagnosis and treatment and medical quality. International tumor diagnosis and treatment methods such as surgery, radiotherapy, chemotherapy, intervention, immunity, genetics and traditional Chinese medicine are all available. The diagnosis and treatment level of nasopharyngeal cancer and 5-year survival rate have reached the international advanced level. Other common tumors such as head and neck cancer, esophageal cancer, lung cancer, breast cancer, liver cancer, colorectal cancer, cervical cancer, ovarian cancer, lymphoma, etc., have reached the domestic first-class and international advanced level of clinical treatment efficacy and clinical research. In order to further improve the quality of medical treatment, the center takes the lead in launching the chief expert responsibility system for single disease of tumor in the country, formulating comprehensive treatment specifications for various common tumors and determining the optimal individualized treatment plan according to the condition and actual situation of each patient to achieve the best therapeutic effect.
2010
The center has more than 1,500 employees, including 236 senior titles, 2 academicians of the Chinese Academy of Sciences (including 1 part-time), 48 doctoral supervisors, 97 master's supervisors, and more than 350 graduate students in training. There are 70 oncology specialists and physicians in training***, more than 90 one-year oncology specialist trainees, master's degree enrollment specialties: oncology, imaging medicine and nuclear medicine, anesthesiology, molecular medicine; doctoral degree enrollment specialties: oncology, molecular medicine.
The center has 1,072 beds, admitting patients from all over the country and Southeast Asia, with an annual outpatient volume of 370,000 and more than 34,000 discharges, the number steadily increasing year by year. It has specialties such as Internal Medicine, Radiotherapy, Nasopharyngeal, Head and Neck, Thoracic, Breast, Colorectal, Gastro-Pancreatic, Hepatobiliary, Urological Oncology Surgery, Neuro-Oncology Surgery, Gynecology, Imaging and Minimally Invasive Intervention Center, Traditional Chinese Medicine, Hematology-Oncology, Endoscopy-Laser & Biological Therapy and so on.
The center provides comprehensive treatment for patients, including surgery, radiotherapy, chemotherapy, intervention, minimally invasive, biological and traditional Chinese medicine, etc. In 1998, the center took the lead in launching the system of the chief specialist in charge of a single type of tumor in the domestic counterparts, and formulated and implemented the standard of comprehensive treatment of a single type of tumor, creating a personalized treatment plan for each patient, and opening a direction for the oncology hospital to give full play to its own characteristics, and attracting the attention of the medical profession. This has opened up a direction for tumor hospitals to give full play to their own characteristics, and attracted many domestic counterparts to come to exchange and learn. The center has constantly revised and improved the diagnosis and treatment standard of each tumor and formulated the clinical path for each major disease, and in August 2008, the center launched the multidisciplinary joint outpatient clinic for eight common tumors, which facilitates patients to seek medical treatment, especially for the difficult patients, and brings gospel to the patients, and receives wide attention from the major media and high praise from the society. Head and Neck Department
Scale and Advantages:
Now there are 2 wards with 72 beds. There are 7 professionals with senior titles, including 2 doctoral supervisors and 4 master's supervisors. It is one of the head and neck tumor specialties with the strongest professional and technical force in China, and has a high academic status at home and abroad. Characteristics and Achievements:
Mainly diagnoses and treats benign and malignant tumors of the head and neck, including: laryngeal cancer, thyroid tumors, oral cavity tumors, salivary gland tumors, nasal and paranasal sinus tumors, nasopharyngeal, oropharyngeal and laryngopharyngeal cancers, nasopharyngeal fibrous hemangiomas, skin tumors of the head and neck, and choroidal tumors, and ophthalmological tumors. After years of improvement and refinement, cervical lymph node dissection has become a standardized procedure, and its characteristics have been recognized by domestic and international academic circles. On the basis of years of scientific research and clinical study, radical surgery and comprehensive treatment of laryngeal cancer with preservation of laryngeal function have been carried out to improve the survival quality of laryngeal cancer patients. With comprehensive treatment methods such as surgery combined with chemotherapy and localized stereoscopic radiation therapy, the Department of Nasopharyngeal Carcinoma has implemented rescue treatment for lesions after the failure of radiation therapy, which has achieved better therapeutic effect. As for the treatment of oral cavity tumors, the company is the first in China to apply microwave tissue coagulation therapy to treat cancer of the floor of the mouth and middle and advanced tongue cancer, which enables the patients to preserve the jawbone and facial appearance on the basis of radical treatment of tumors; and carries out the research on sentinel lymph nodes of oral cavity cancer and the study on partitioned lymph node dissection, which improves the quality of patients' life after the operation.
Based on the research results of statistical multifactorial analysis, the program of thyroid lobectomy with isthmus resection or subtotal resection of gland lobe was proposed for the treatment of single thyroid nodule; based on the statistics of many years' data, it was proposed that thyroid lobectomy with isthmus resection could be a reasonable operation for differentiated thyroid cancer, which improved the quality of life of patients. Carry out combined craniofacial surgery to treat paranasal sinus, or scalp malignant tumors that invade the base of the skull, intracranial. Local flaps are used for postoperative defects of middle and advanced head and neck malignant tumors. A variety of methods such as myocutaneous flap or free tissue flap were used for repair, which resulted in a better recovery of the patient's appearance and function and improved the patient's quality of life. We advocate the comprehensive treatment of locally advanced head and neck malignant tumors, including chemotherapy, radiotherapy and surgery, and actively explore the reasonable treatment of locally advanced head and neck malignant tumors. She has developed chemotherapy for the treatment of head and neck choroidal tumor, and achieved good therapeutic effect.
Thoracic Department
Thoracic Department is an important part of Surgical Oncology of Cancer Prevention and Control Center, which is a chest tumor specialty established earlier in China. After years of development and efforts of several generations, it is now the thoracic tumor specialty with the strongest technical force in South China. The Department of Thoracic Tumor is full of talents, currently there are 4 professors and chief physicians (including 1 doctoral supervisor and 6 master's supervisors), 5 associate professors, 5 attending physicians and 4 residents. There are currently 8 doctors and 9 masters (including students). Among them, Prof. Rong Tiehua is the supervisor of doctoral students, the chief expert of esophageal cancer and lung cancer, the secretary of the Party Committee of the Center, the executive member of Esophageal Cancer Specialized Committee of the Chinese Anti-Cancer Association, and the chairman of Esophageal Cancer Specialized Committee of Guangdong Province of the Chinese Anti-Cancer Association. Dr. Yang Mingtian is the chief specialist of breast cancer and the chairman of the Guangdong Breast Cancer Committee of the Chinese Anti-Cancer Association.
The Department of Thoracic Medicine mainly diagnoses and treats benign and malignant tumors of the chest, including lung tumors, esophageal tumors, breast tumors, mediastinal tumors, pleural tumors and chest wall tumors. These include the most common esophageal cancer, lung cancer and breast cancer. The Department of Thoracic Surgery now has three wards with 108 beds, and over the past 30 years, the department has carried out more than 3,000 esophageal cancer surgeries, more than 4,000 lung cancer surgeries, and more than 5,000 breast cancer surgeries, and accumulated rich experience in the surgical treatments of esophageal and cardia cancers, lung cancers, breast cancers, mediastinal tumors, and thoracic wall tumors as well as in the comprehensive treatments, and the five-year survival rate of esophageal cancers is 39.2% after surgery, and the five-year survival rate of lung cancers is 39% after surgery. The 5-year survival rate of esophageal cancer is 39.2%, the 5-year survival rate of lung cancer is 39%, among which the 5-year survival rate of stage II non-small cell lung cancer is as high as 70%, the 10-year survival rate of breast cancer is 65%, and the long-term efficacy of the major cancers after treatment has reached the domestic advanced level.
The medical staff of the department constantly absorbs and applies the advanced scientific research achievements and technical experience at home and abroad, carries out new surgical methods, and constantly improves the success rate of surgery. They are the first to apply tracheoplasty, bronchoplasty, pulmonary arterioplasty and partial left atrial resection to the surgical treatment of lung cancer, and take the lead in carrying out esophageal lumpectomy, esophageal dissection, one-stage resection of double lung tumors via median sternotomy, resection of huge tumors on the chest wall with chest wall sandwich reconstruction, breast cancer breast preservation surgery and breast reconstruction, and hand-assisted thoracoscopic treatment for Double lung metastases, etc. The number of cases of esophageal stenting, tracheal and bronchial stenting and mediastinoscopic diagnostic examination of difficult diseases is leading in the country. At present, it is equipped with the most advanced esophageal ultrasonography instrument in China. It has undertaken 12 scientific research projects*** at the national level, the Ministry of Health, the Provincial Science and Technology Commission and the Department of Health. Every year, it publishes more than 15 high-quality papers at home and abroad.
Abdomenology
Abdomenology is one of the important departments of Sun Yat-sen University Cancer Center, with a long history of 36 years. At present **** there are 12 physicians, 4 chief physicians and professors, 3 deputy chief physicians and associate professors, 2 attending physicians, including 1 doctoral supervisor and 3 master's supervisors. There are 3 doctoral students and 7 master's students in the program. Training of advanced doctors from dozens of provinces and regions across the country.
The main diseases treated in the Department of Abdomen include: colorectal tumors, gastric tumors, breast tumors, pancreatic tumors, retroperitoneal tumors, renal tumors, bladder tumors, prostate cancers, testicular tumors, and tumors of the skin, bone and soft tissue. The treatment means of our department is comprehensive treatment mainly based on surgery, especially the diagnosis and treatment of colorectal cancer is at the national advanced level. Our work and efforts in early detection, early diagnosis, timely treatment and reduction of postoperative recurrence and metastasis of abdominal tumors have received good therapeutic effects and have been affirmed by our peers.
Every year, we treat about 1,000 patients from all over the country, and most of them have recovered through our careful treatment and care, and quite a number of them have been cured of "stubborn diseases" by radical treatment. Many patients have expressed their heartfelt thanks for our work, and the leaders of the institution have given us a high evaluation, and we have been awarded as "Advanced Civilized Department" for many times. We have won the trust of the general public with our exquisite medical skills and noble medical ethics, and have become one of the nationally renowned and major abdominal tumor prevention and treatment centers in South China.
Now we have 70 inpatient beds. Among them, the diagnosis and treatment level of colorectal cancer is at the domestic advanced level, especially the care of artificial anus after Miles' operation for rectal cancer. We held a provincial training course for colostomy therapists in 1996, and in 1998, approved by the State Continuing Education Office, we held a national education program: training course for intestinal stoma therapists, which is now in its fourth session, with trainees coming from large general hospitals and specialized hospitals such as Beijing, Shanghai, Tianjin, etc., as well as from a wide range of grass-root level hospitals; there are nursing workers as well as doctors of senior titles. The number of trainees has been increasing year by year, and in 2001, the number of trainees in the fourth session reached 50, but there are still many medical and nursing personnel who regret that they could not be recruited. What is even more exciting for the majority of ostomates and health care workers is that the first school for ostomates in China, the School of Ostomates at Zhongshan Medical University, was formally established in March 2001 with the efforts of Prof. Wanderson of the Department of Ostomy and the health care workers and the care and support of the leaders of the institution, and successfully trained the first batch of 11 trainees, who are the first batch of trainees trained in our country to hold the internationally accredited certificate of stoma treatment issued by the World Association of Ostomates. They are also the first group of trainees trained by our country to hold the certificate of stoma therapist with international certification issued by the World Ostomy Association. Over the years, our department has trained nearly 1,000 stoma therapists with specialized knowledge and skills, and has gradually become a training base for stoma therapists in China.
In order to prevent postoperative liver metastasis and abdominal implantation of gastrointestinal tumors, the department carries out intraoperative enteral chemotherapy, portal vein 5-FU infusion and abdominal chemotherapy; postoperative continuous portal vein 5-FU infusion and abdominal chemotherapy pump implantation. He edited Clinical Oncology and Community Oncology; co-edited Hepatobiliary Oncology; participated in the preparation of Therapeutics of Liver Disease and Diagnostic Norms for Common Malignant Tumors in China (Third Subsection Colorectal Cancer); co-translated Surgical Oncology and Cancer Chemotherapy: Principles and Practice. He has chaired several international, national and regional conferences, including the 1st China-Australia-New Zealand International Oncology Conference, and the annual meetings and paper exchanges of the Colorectal Cancer Specialized Committee of the Guangdong Anti-Cancer Association.
Hepatobiliary Department
Hepatobiliary Department is one of the key departments in Sun Yat-sen University Cancer Hospital. As early as 1964, South China Cancer Hospital (the predecessor of Sun Yat-sen University Cancer Hospital) was established and devoted to the research of primary liver cancer, which is the earliest base in South China to engage in the research of liver cancer, and one of the earliest hospitals in China to carry out the surgical treatment of liver cancer, and has been tasked with the research of prevention and treatment of liver cancer in the region over the past years. Over the past 30 years, it has made gratifying achievements. It has successively set up the Liver Cancer Research Laboratory of Sun Yat-sen Medical University, the Guangdong Liver Cancer Research Collaboration Group, and specialized wards, and in 1998, it independently formed the Department of Hepatobiliary Diseases of Date and Liver Cancer Research Center of Sun Yat-sen Medical University. It is the only specialized liver cancer treatment department in China that integrates surgery, intervention, radiotherapy, Chinese medicine and traditional Chinese medicine, etc., which can choose the most optimal single-disease treatment plan for patients and achieve the best therapeutic effect. The Department of Hepatobiliary Medicine has 62 specialized beds, 15 technical backbones in the whole department***, 8 of whom have the title of associate senior or above, 4 postgraduates, 1 doctoral student, 1 postdoctoral student, and other related professionals to form a 25-member liver cancer single-case treatment and management team, which is in charge of the admission and treatment of liver cancer in the whole hospital and the formulation of the most optimal treatment plan.
Two ultrasound diagnostic machines (equipped with multi-functional ultrasound probes for preoperative and intraoperative diagnosis), one DSA diagnostic and therapeutic instrument, one radiofrequency therapeutic instrument of Daron Company of the United States, and other advanced equipment such as advanced CT, MRI and radiotherapy machines of the Cancer Hospital have been equipped, so that the patients with liver disease can be accurately diagnosed and treated. The treatment of primary liver cancer includes surgical resection, interventional therapy, radiotherapy, chemotherapy and other treatment means. Among them, surgical resection has the best efficacy, and the rate of surgical resection of liver cancer has been increasing with the continuous improvement of surgical techniques. Since 1980s, our department has been carrying out the improvement of surgical pattern of liver cancer instead of previous regular hepatectomy, and it is the first time in China to carry out a comprehensive study on the indications and technical operation efficacy of irregular hepatectomy. It was confirmed that this technique is easy to operate, especially for patients with combined cirrhosis, which can increase the surgical resection rate and improve the overall efficacy of liver cancer. So far, nearly 2,000 cases of liver cancer have been surgically resected in our department (one of the three hospitals with the highest number of resected cases in China at present), and the overall 5-year survival rate of the patients after their operation has reached 40%, and the 5-year survival rate of the patients after the operation of small liver cancers can reach more than 55%, and many of the patients have been healthy and survived for more than 20 years after the operation.
Aiming at the high recurrence rate and poor efficacy of liver cancer after surgery, our department was the first in China to carry out the research of utilizing postoperative adjuvant interventional therapy to reduce the recurrence rate and improve the survival period of liver cancer after surgery and obtained the fund of scientific research from the State Education Commission and the Ministry of Health, which proved that postoperative interventional therapy could reduce the recurrence rate and improve the survival rate. Meanwhile, combining with molecular biology and other basic researches, we have proposed for the first time in China the diagnostic standard and auxiliary treatment measures for the high-risk group of postoperative recurrence of hepatocellular carcinoma. Since 1989, our department has carried out interventional therapy for more than 2,000 cases of liver cancer for more than 10 years, and achieved satisfactory curative effects, many patients were given the opportunity of second-stage resection, and the survival period of many patients with middle- and late-stage liver cancer has been prolonged. 1996, we have carried out non-vascular interventional therapy under the guidance of ultrasound, including anhydrous alcohol intratumoral injection, microwave therapy, radiofrequency treatment, and other local treatments for liver cancer, and these emerging micro-medicine interventional therapy can improve the survival period. These emerging minimally invasive techniques provide new treatment pathways for liver cancer patients. While continuously improving the level of clinical medical technology, our department also actively carries out various scientific researches to provide reliable theoretical basis for clinical progress. With the deepening of research on liver cancer, it is difficult to improve the efficacy of single surgical resection or interventional therapy, so how to integrate surgical technology, interventional therapy, radiotherapy, traditional Chinese medicine and other means is precisely the important content of the National Ninth Five-Year Plan - Comparative Research on Surgery and Interventional Therapy of Liver Cancer, which is undertaken by our department. Through the above research projects, a set of optimized treatment mode of liver cancer integrating surgery, intervention, radiotherapy, Chinese medicine and other techniques has been found out initially, and a more in-depth research has been made on the pathology, molecular biology, liver reserve function and drug sensitivity of liver cancer.
Gynecology
Gynecology, as an important part of the surgical system of Sun Yat-sen University Cancer Prevention and Treatment Center, has trained a group of gynecologists with skillful surgical operation through the unremitting efforts and hard work of several generations of renowned veteran professors and specialists of gynecological oncology for more than three decades, and has been responsible for not only heavy clinical work, but also scientific research and teaching tasks in gynecological oncology, with its strong clinical and scientific research strength. With its strong clinical research strength, it not only carries out heavy clinical work, but also undertakes scientific research and teaching tasks in gynecological oncology, and has a high academic status at home and abroad. There are 15 doctors on the staff, including 4 with senior titles, 6 with deputy senior titles, 3 with intermediate titles, 2 residents, and 6 master's degree supervisors. The Department of Gynecology has 70 beds.
Medical and Clinical
After years of clinical practice, the department has formulated routine diagnosis and treatment plans for common gynecological tumors, such as cervical cancer, endometrial cancer, ovarian cancer, vulvar cancer, malignant trophoblastic tumors, uterine fibroids, etc., and has achieved good therapeutic effects, especially the diagnosis, treatment and nursing level of cervical and ovarian cancers have reached the domestic and international advanced level.
The method of radical cervical cancer surgery has been boldly improved, and the operation time has been significantly shortened. The 5-year survival of cervical cancer patients is 80%. Over the years, experts of our department have conducted surgical exchanges abroad and across the country, winning wide praise from peers. Ovarian cancer mortality rate is the highest among gynecological cancers. Thorough surgery is the key to improve the survival rate of ovarian cancer patients. Ovarian cancer cytoreductive surgery is difficult to perform, and the surgeon needs to master the surgical skills of gynecology as well as the surgical foundation of abdominal surgery and urology. Some experienced gynecologists in the department are capable of performing cytoreductive surgery for ovarian cancer. In 1964, our department was the first to propose and apply intraperitoneal chemotherapy for ovarian cancer in China, and summarized and formulated a series of chemotherapy protocols based on years of experience and clinical research results. The 5-year survival rate of stage I ovarian cancer treated by our department is more than 90%, and the 5-year survival rate of stage II and III ovarian cancer patients who have completed the treatment according to the plan is 60%, which is significantly higher than the overall 5-year survival rate of 30-40% reported in the literature. In addition to surgery, chemotherapy is a major feature. Over the years, we have carried out intraperitoneal chemotherapy, local chemotherapy by cannulation of the inferior abdominal wall artery, superficial temporal artery of the obturator artery and superior thyroid artery, etc. Combined with systemic chemotherapy, surgery and radiotherapy, it has significantly improved the efficacy of advanced cancerous tumors and recurrent tumors in the gynecology department, and the quality of life of the patients.
Scientific research and academic exchanges
Medicine and scientific research complement each other and promote each other. In addition to clinical work, the department also attaches great importance to scientific research and strengthen the connotation of construction. Every year, we publish more than 10 papers in national core journals. The subjects being undertaken by the department include: the experimental study of P53 gene in the treatment of high-risk cervical cancer, the study on the clinical significance of cell cycle regulating genes in epithelial ovarian cancer, the study of predicting the efficacy of chemotherapy and sensitivity of chemotherapeutic drugs for malignant tumors, and the study on the clinical significance of cell cycle regulating genes in epithelial ovarian cancer. Drug efficacy and sensitivity of chemotherapeutic drugs in malignant tumors", "Clinical research on reversing drug resistance in ovarian cancer", "Tumor suppressor gene P53 and arterial cannulation chemotherapy in the treatment of pelvic recurrence of cervical cancer", "Fund of the Provincial Department of Health", "Fund of the Provincial Administration of Traditional Chinese Medicine". Research on Combination of Traditional Chinese Medicine and Western Medicine in the Treatment of Advanced Cervical Cancer", "Experimental Study on HeLa Cell Apoptosis Induced by Elemene in Cervical Cancer", "Experimental and Clinical Study on Reversal of Multidrug Resistance in Ovarian Cancer by Combination of Chemotherapy with Powdered Porphyrine", and the Center Foundation. Research", "Experimental and clinical study on reversal of multidrug resistance in ovarian cancer by combination chemotherapy with powdered antibiotic base", the center fund and other funds. The research direction of most of the topics is the hotspot of gynecologic oncology research in recent years.
He has also edited the books "Diagnosis and Treatment of Ovarian Malignant Tumors", "Diagnosis and Treatment of Uterine Cervical Cancer", "Diagnosis and Treatment of Vulvar Tumors", "New Surgery in Obstetrics and Gynecology", "Gynecologic Oncology" and so on.
Actively strengthening the communication and cooperation with domestic and foreign counterparts, and actively participating in relevant national academic conferences. Famous professors from home and abroad have been invited to give lectures for many times. Experts of our department have been to Canada, Australia, Hong Kong and other places for academic exchanges, and have successfully hosted the fourth national and international gynecologic oncology academic conference and the national gynecologic oncology study class, expanding its influence.
Talent Team and Teaching
There is already a team with good medical, scientific research and teaching quality. It undertakes a variety of teaching tasks for university, undergraduate, postgraduate and advanced students. For two consecutive years, it has hosted the national continuing medical education program on ovarian cancer. Young and middle-aged cadres are selected to go to Australia, Hong Kong and other places for training, so as to absorb the advanced technology at home and abroad and enhance their scientific research strength. In addition, it also encourages young and middle-aged physicians to actively carry out scientific research on the basis of completing clinical work, and has formed a favorable academic atmosphere.
The development of the discipline is directed towards maintaining and consolidating the clinical advantages of the department and focusing on carrying out some clinically relevant basic research. We are striving to bring the clinical research level of our department to a new level and to be in line with the international level.